

Claims

1. A pharmaceutical composition comprising a disrupted cell suspension of *Monilia albicans* and euglobulin as effective ingredients.

5

2. The pharmaceutical composition as set forth in claim 1, wherein the disrupted cell suspension of the *Monilia albicans* is prepared by culturing the *Monilia albicans* in a liquid culture medium, centrifuging the resulting culture fluid, recovering a supernatant and disrupting collected cells, and mixing the supernatant and a cell lysate after 10 inactivation, wherein the culture fluid contains the *Monilia albicans* of about 1.2×10^9 cfu/ml.

3. The pharmaceutical composition as set forth in claim 1, wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml 15 of the disrupted cell suspension of the *Monilia albicans*.

4. The pharmaceutical composition as set forth in claim 1, 2, or 3, wherein the pharmaceutical composition is used for treating canine distemper.

20 5. The pharmaceutical composition as set forth in claim 1, 2, or 3, wherein the pharmaceutical composition is used for treating cerebral apoplexy, brain injury, neurological dysfunctions, Alzheimer's disease and myoclonus.

6. A method of treating an animal infected with a canine distemper virus,

comprising:

subcutaneously administering to the animal a pharmaceutical composition comprising a disrupted cell suspension of *Monilia albicans* and euglobulin as effective ingredients once to three times daily in a dose of 0.3 ml/kg to 2 ml/kg.

5

7. The method as set forth in claim 6, wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml of the disrupted cell suspension of the *Monilia albicans*.

10

8. The method as set forth in claim 6 or 7, wherein the pharmaceutical composition is administered in combination with a stomach protectant in a dose of 0.2 ml/kg to 0.3 ml/kg and an antibiotic in a dose of 0.3 ml/kg to 0.45 ml/kg once or twice daily.

15

9. The method as set forth in claim 8, wherein the stomach protectant is selected from among metoclopramide hydrochloride, cimetidine and nuxvomica, and the antibiotic is selected from among sulfa drugs, cephalexin drugs, enrofloxacin, penicillin and ampicillin.

20

10. A method of treating an animal with a neurological disorders such as cerebral apoplexy, brain injury, neurological dysfunctions, Alzheimer's disease or myoclonus, comprising:

subcutaneously administering to the animal a pharmaceutical composition comprising a disrupted cell suspension of *Monilia albicans* and euglobulin as effective ingredients once daily in a dose of 0.3 ml/kg to 0.6 ml/kg.

11. The method as set forth in claim 10, wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml of the disrupted cell suspension of the *Monilia albicans*.

5

12. The method as set forth in claim 10 or 11, wherein the pharmaceutical composition is administered in combination with a stomach protectant in a dose of 0.2 ml/kg to 0.3 ml/kg and an antibiotic in a dose of 0.3 ml/kg to 0.45 ml/kg once or twice daily.

10

13. The method as set forth in claim 12, wherein the stomach protectant is selected from among metoclopramide hydrochloride, cimetidine and nuxvomica, and the antibiotic is selected from among sulfa drugs, cepha drugs, enrofloxacin, penicillin and ampicillin.